Study of IMM2510 plus IMM01 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a combination of two experimental drugs, IMM2510 and IMM01, in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed solid tumor that has advanced or spread.
- You must be in good enough physical condition to be up and about (ECOG score 0 or 1).
- You must have adequate organ function, such as your liver, kidneys, and bone marrow working well.
- You cannot have had chemotherapy within the last 3 weeks before starting the study drugs.
- You cannot have untreated or active brain metastases that cause symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a combination of two experimental drugs, IMM2510 and IMM27M, for people with advanced hepatocellular carcinoma (a type of liver cancer) that hasn't responded to other treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.